Article in Oncoimmunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors.
Britney NiemannDivision of Surgical Oncology, Department of Surgery, West Virginia University, Morgantown, WV, USA.ORCID 0000-0002-8129-5220
Abby IveyCancer Cell Biology, West Virginia University, Morgantown, WV, USA.
Quinn HopenDepartment of Microbiology, Immunology and Cell Biology, West Virginia University, Morgantown, WV, USA.
Duaa DakhlallahDivision of Surgical Oncology, Department of Surgery, West Virginia University, Morgantown, WV, USA.
Kathleen BrundageDepartment of Microbiology, Immunology and Cell Biology, West Virginia University, Morgantown, WV, USA.
Nicole MihalikDepartment of Microbiology, Immunology and Cell Biology, West Virginia University, Morgantown, WV, USA.
Timothy EubankCancer Cell Biology, West Virginia University, Morgantown, WV, USA.
Brian A BooneDivision of Surgical Oncology, Department of Surgery, West Virginia University, Morgantown, WV, USA.
Funding
West Virginia IDEA-CTRU54GM104942 · NIGMS · WEST VIRGINIA UNIVERSITY · PI Laura F. Gibson · 2012 to 2026
$81.0M
WV INBRE: The Inhibitor of Growth Family Member 4 (ING4) inhibits L-Type Amino Acid Transporter 1 (LAT1) expression to suppress Breast CancerP20GM103434 · NIGMS · MARSHALL UNIVERSITY · PI GARY O RANKIN · 2012 to 2026
$61.1M
WVU Flow Cytometry and Single Cell Core Facility (FCSCCF)P20GM121322 · NIGMS · WEST VIRGINIA UNIVERSITY · PI Karen H Martin · 2018 to 2026
$22.4M
In vivo monitoring of tumor microenvironment regulation for macrophagesR01CA194013 · NCI · WEST VIRGINIA UNIVERSITY · PI Timothy D Eubank, Valery V Khramtsov · 2015 to 2026
$3.5M
Profiling chemical tumor microenvironment: Application for diagnostics & therapyR01CA192064 · NCI · WEST VIRGINIA UNIVERSITY · PI EUBANK, TIMOTHY D, KHRAMTSOV, VALERY V · 2015 to 2024
$3.4M
Cytek 3-laser AuroraS10OD028605 · OD · WEST VIRGINIA UNIVERSITY · PI BRUNDAGE, KATHLEEN M · 2021 to 2021
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with poor survival. The immunosuppressive tumor microenvironment (TME) drives resistance to therapy, including immunotherapy. This may be, in part, mediated by the formation of neutrophil extracellular traps (NETs), formed when neutrophils release their intracellular contents. NETs are elevated in PDAC and are associated with nearly every stage of tumor progression. We investigated the influence of NETs on the PDAC TME and immunotherapy response. An orthotopic PDAC model was utilized in C57BJ6 or PAD4
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.